The Fort Worth Press - Emerging Growth Research Maintains Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Strategic U.S. Market Entry

USD -
AED 3.6725
AFN 63.498714
ALL 82.898186
AMD 377.20221
ANG 1.790083
AOA 917.000143
ARS 1376.63099
AUD 1.440029
AWG 1.80225
AZN 1.702556
BAM 1.686202
BBD 2.015182
BDT 122.789623
BGN 1.709309
BHD 0.377574
BIF 2970
BMD 1
BND 1.279061
BOB 6.913944
BRL 5.238103
BSD 1.000522
BTN 94.115213
BWP 13.635619
BYN 2.965482
BYR 19600
BZD 2.012485
CAD 1.381501
CDF 2280.000526
CHF 0.791505
CLF 0.023228
CLP 917.189797
CNY 6.901501
CNH 6.903795
COP 3701.45
CRC 465.236584
CUC 1
CUP 26.5
CVE 95.625012
CZK 21.156905
DJF 177.719503
DKK 6.46211
DOP 60.374986
DZD 132.724008
EGP 52.534297
ERN 15
ETB 157.326049
EUR 0.86476
FJD 2.228204
FKP 0.747226
GBP 0.748305
GEL 2.695017
GGP 0.747226
GHS 10.949746
GIP 0.747226
GMD 73.533829
GNF 8780.000182
GTQ 7.657854
GYD 209.347342
HKD 7.818985
HNL 26.519756
HRK 6.5177
HTG 131.207187
HUF 334.957498
IDR 17041.4
ILS 3.11585
IMP 0.747226
INR 94.58805
IQD 1310
IRR 1313149.999855
ISK 123.839714
JEP 0.747226
JMD 157.605908
JOD 0.708983
JPY 159.350503
KES 129.749764
KGS 87.449198
KHR 4012.999761
KMF 426.999612
KPW 900.014346
KRW 1503.620076
KWD 0.30659
KYD 0.833829
KZT 482.773486
LAK 21585.000353
LBP 89549.999638
LKR 314.680461
LRD 183.649893
LSL 16.940125
LTL 2.95274
LVL 0.60489
LYD 6.374979
MAD 9.327502
MDL 17.495667
MGA 4170.000264
MKD 53.305946
MMK 2100.167588
MNT 3569.46809
MOP 8.057787
MRU 40.129725
MUR 46.459723
MVR 15.450396
MWK 1737.000057
MXN 17.77755
MYR 3.964495
MZN 63.901438
NAD 16.930012
NGN 1385.459778
NIO 36.719792
NOK 9.687115
NPR 150.586937
NZD 1.72225
OMR 0.384467
PAB 1.000578
PEN 3.460501
PGK 4.309497
PHP 60.060035
PKR 279.049985
PLN 3.69755
PYG 6510.184287
QAR 3.644006
RON 4.406198
RSD 101.569038
RUB 81.000744
RWF 1460
SAR 3.751679
SBD 8.042037
SCR 13.699685
SDG 600.999739
SEK 9.3519
SGD 1.281051
SHP 0.750259
SLE 24.549731
SLL 20969.510825
SOS 571.000463
SRD 37.340503
STD 20697.981008
STN 21.4
SVC 8.755292
SYP 110.948257
SZL 16.8977
THB 32.779488
TJS 9.58109
TMT 3.5
TND 2.937501
TOP 2.40776
TRY 44.359899
TTD 6.803525
TWD 31.950899
TZS 2570.059035
UAH 43.92958
UGX 3702.186911
UYU 40.504889
UZS 12199.999601
VES 462.09036
VND 26350
VUV 119.508072
WST 2.738201
XAF 565.560619
XAG 0.014069
XAU 0.000222
XCD 2.70255
XCG 1.803352
XDR 0.702492
XOF 563.50327
XPF 103.450387
YER 238.649487
ZAR 16.98853
ZMK 9001.203419
ZMW 18.736367
ZWL 321.999592
  • CMSD

    0.0500

    22.68

    +0.22%

  • BCC

    1.0800

    74.65

    +1.45%

  • BCE

    -0.3400

    25.49

    -1.33%

  • RBGPF

    -13.5000

    69

    -19.57%

  • RIO

    0.7700

    87.54

    +0.88%

  • CMSC

    0.0400

    22.91

    +0.17%

  • BTI

    0.6900

    58.45

    +1.18%

  • BP

    0.6200

    45.41

    +1.37%

  • GSK

    1.7500

    54.7

    +3.2%

  • AZN

    1.3600

    187.14

    +0.73%

  • JRI

    0.2400

    12.1

    +1.98%

  • NGG

    1.9600

    84.29

    +2.33%

  • RYCEF

    0.3000

    15.9

    +1.89%

  • RELX

    0.0100

    32.47

    +0.03%

  • VOD

    0.0600

    14.72

    +0.41%

Emerging Growth Research Maintains Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Strategic U.S. Market Entry
Emerging Growth Research Maintains Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Strategic U.S. Market Entry

Emerging Growth Research Maintains Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Strategic U.S. Market Entry

NEW YORK, NY / ACCESS Newswire / January 7, 2026 / Emerging Growth Research today announced the release of its Flash Report on SBC Medical Group Holdings, Inc. (Nasdaq:SBC), maintaining a Buy-Extended rating and its 12-month price target of $9.00, representing significant upside from the Company's closing price of $4.44 on January 6, 2026.

Text size:

The Flash Report highlights SBC's major milestone entry into the United States medical aesthetics market through a strategic minority equity investment and structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain. This transaction marks a pivotal expansion in SBC's global growth strategy and follows the Company's prudent phased approach to international M&A.

Key Highlights from the Flash Report:

  • U.S. Market Entry: SBC has completed a strategic minority equity investment in OrangeTwist alongside longstanding shareholders Hildred Capital and Athyrium Capital, marking the beginning of full-scale, multi-year strategic expansion in the key U.S. medical aesthetics growth market.

  • Strategic Partnership: OrangeTwist operates 24 locations across 6 U.S. states, specializing in non-invasive aesthetic treatments with strong medical oversight and data-driven clinical operations. The company offers a comprehensive portfolio of injectable, energy-based, and regenerative treatments.

  • Operational Synergies: Both companies will pursue joint operations leveraging cross-border synergies between the U.S. and Asia to support long-term growth opportunities. OrangeTwist's advanced management system integrating procurement, clinical workflows, and real-time KPI tracking aligns with SBC's operational expertise.

  • Revenue Stabilization: Following year-over-year revenue pressure through early 2025, SBC's revenue growth stabilized sequentially in Q3:25, with management expecting renewed growth in early-2026 supported by global expansion initiatives.

  • Strong Financial Position: SBC maintains a robust balance sheet with ample net cash (approximately 40% of current market capitalization) and minimal debt (Debt/MV Equity of just 5%), providing significant financial flexibility for strategic investments and M&A activities.

  • Prudent Expansion Strategy: SBC's international expansion follows a disciplined 3-phase implementation process: entry, scale, and leadership. This approach involves partnering with high-performing regional operators, deploying SBC's differentiated operating expertise, and securing first-mover advantages.

  • Significant Upside Potential: Despite strong recovery from ~$3.00/share lows, SBC shares remain heavily undervalued both traditionally and via DCF analysis. The firm's analysis indicates substantial upside, especially net of the Company's ample cash position.

According to Emerging Growth Research's analysis, SBC has successfully navigated near-term competitive pressures while maintaining its position as a cash generation machine with 25 years of operational excellence. The Company's accomplished founder and management team have shepherded SBC from a solo clinic in 2000 to become a global cosmetic treatment center franchiser with operations across Japan, Vietnam, Thailand, Singapore, and now the United States.

The OrangeTwist investment represents a major milestone in SBC's long-term vision to expand from 258 clinics currently to 1,000 clinics over ten years, supported by domestic organic growth and strategic M&A across key global markets.

For a copy of the full Flash Report, please visit:

or

About SBC Medical Group Holdings, Inc.

Founded in 2000 as Shonan Beauty Clinic in Japan, SBC Medical Group Holdings, Inc. (Nasdaq: SBC) has grown into a leading global healthcare management company specializing in cosmetic treatments. Through its franchise model, SBC operates across dermatology, aesthetic surgery, hair removal, orthopedics, ophthalmology, fertility, dentistry, and related services. With operations concentrated in Japan and growing footprints in Vietnam, Thailand, Singapore, and the United States, SBC continues to pursue international expansion.

For more information, please visit https://sbc-holdings.com/en.

About OrangeTwist

OrangeTwist is a leading U.S.-based MedSpa chain specializing in non-invasive aesthetic treatments at 24 locations across 6 U.S. states. With strong medical oversight and data-driven clinical operations, OrangeTwist offers a comprehensive portfolio of injectable, energy-based, and regenerative treatments supported by advanced management systems for operational consistency and scalable growth.

Contact:

Emerging Growth Research
[email protected]
www.EmergingGrowth.com

Forward-Looking Statements

This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for SBC Medical Group Holdings, Inc. that are subject to risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These include but are not limited to statements regarding U.S. market expansion, the OrangeTwist partnership, revenue growth resumption in 2026, clinic expansion targets, global M&A strategy, cross-border operational synergies, and valuation projections. Actual results could differ materially due to competitive, regulatory, operational, international expansion risks, integration challenges, or market risks.

SOURCE: SBC Medical Group Holdings Incorporated



View the original press release on ACCESS Newswire

S.Weaver--TFWP